Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer

D. Kelsen, Richard J. Gralla, M. Stoopler, E. Casper, E. Cheng, C. Kosloff, R. Golbey

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Seventy-four patients with non-small cell lung cancer were treated in a prospective, randomized trial either with a four-drug combination of cisplatin, doxorubicin, cyclophosphamide, and vindesine (PACE) or with a three-drug combination of cisplatin, cyclopyhosphamide, and vindesine (PCE). None of these patients had received prior chemotherapy, and all had a Karnofsky performance status of at least 60. Of 68 evaluable patients, 21 (31%) had complete or partial remissions. Response rates for PACE and PCE were similar, and there was no difference in response rates for patients with adenocarcinoma or epidermoid cancer. The median duration of remission was 10 months (range, 2-26+); five patients are still in remission (median, 18+ months; range, 17+ to 26+). The median duration of survival for responding patients (complete or partial) was 18 months. Toxic effects, including mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, were manageable in general. The response rates and remission durations for PACE and PCE are similar to those seen with the two-drug combination of cisplatin and vindesine, and toxic effects are similar. Thus, the addition of doxorubicin and/or cyclophosphamide adds no advantage to the use of the cisplatin and vindesine combination alone.

Original languageEnglish (US)
Pages (from-to)247-251
Number of pages5
JournalCancer Treatment Reports
Volume66
Issue number2
StatePublished - 1982
Externally publishedYes

Fingerprint

Vindesine
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Doxorubicin
Cyclophosphamide
Cisplatin
Drug Combinations
Poisons
Karnofsky Performance Status
Peripheral Nervous System Diseases
Adenocarcinoma
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kelsen, D., Gralla, R. J., Stoopler, M., Casper, E., Cheng, E., Kosloff, C., & Golbey, R. (1982). Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treatment Reports, 66(2), 247-251.

Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. / Kelsen, D.; Gralla, Richard J.; Stoopler, M.; Casper, E.; Cheng, E.; Kosloff, C.; Golbey, R.

In: Cancer Treatment Reports, Vol. 66, No. 2, 1982, p. 247-251.

Research output: Contribution to journalArticle

Kelsen, D, Gralla, RJ, Stoopler, M, Casper, E, Cheng, E, Kosloff, C & Golbey, R 1982, 'Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer', Cancer Treatment Reports, vol. 66, no. 2, pp. 247-251.
Kelsen D, Gralla RJ, Stoopler M, Casper E, Cheng E, Kosloff C et al. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treatment Reports. 1982;66(2):247-251.
Kelsen, D. ; Gralla, Richard J. ; Stoopler, M. ; Casper, E. ; Cheng, E. ; Kosloff, C. ; Golbey, R. / Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 2. pp. 247-251.
@article{aabd4c81788a491c9238a4ff2aaecc0b,
title = "Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer",
abstract = "Seventy-four patients with non-small cell lung cancer were treated in a prospective, randomized trial either with a four-drug combination of cisplatin, doxorubicin, cyclophosphamide, and vindesine (PACE) or with a three-drug combination of cisplatin, cyclopyhosphamide, and vindesine (PCE). None of these patients had received prior chemotherapy, and all had a Karnofsky performance status of at least 60. Of 68 evaluable patients, 21 (31{\%}) had complete or partial remissions. Response rates for PACE and PCE were similar, and there was no difference in response rates for patients with adenocarcinoma or epidermoid cancer. The median duration of remission was 10 months (range, 2-26+); five patients are still in remission (median, 18+ months; range, 17+ to 26+). The median duration of survival for responding patients (complete or partial) was 18 months. Toxic effects, including mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, were manageable in general. The response rates and remission durations for PACE and PCE are similar to those seen with the two-drug combination of cisplatin and vindesine, and toxic effects are similar. Thus, the addition of doxorubicin and/or cyclophosphamide adds no advantage to the use of the cisplatin and vindesine combination alone.",
author = "D. Kelsen and Gralla, {Richard J.} and M. Stoopler and E. Casper and E. Cheng and C. Kosloff and R. Golbey",
year = "1982",
language = "English (US)",
volume = "66",
pages = "247--251",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer

AU - Kelsen, D.

AU - Gralla, Richard J.

AU - Stoopler, M.

AU - Casper, E.

AU - Cheng, E.

AU - Kosloff, C.

AU - Golbey, R.

PY - 1982

Y1 - 1982

N2 - Seventy-four patients with non-small cell lung cancer were treated in a prospective, randomized trial either with a four-drug combination of cisplatin, doxorubicin, cyclophosphamide, and vindesine (PACE) or with a three-drug combination of cisplatin, cyclopyhosphamide, and vindesine (PCE). None of these patients had received prior chemotherapy, and all had a Karnofsky performance status of at least 60. Of 68 evaluable patients, 21 (31%) had complete or partial remissions. Response rates for PACE and PCE were similar, and there was no difference in response rates for patients with adenocarcinoma or epidermoid cancer. The median duration of remission was 10 months (range, 2-26+); five patients are still in remission (median, 18+ months; range, 17+ to 26+). The median duration of survival for responding patients (complete or partial) was 18 months. Toxic effects, including mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, were manageable in general. The response rates and remission durations for PACE and PCE are similar to those seen with the two-drug combination of cisplatin and vindesine, and toxic effects are similar. Thus, the addition of doxorubicin and/or cyclophosphamide adds no advantage to the use of the cisplatin and vindesine combination alone.

AB - Seventy-four patients with non-small cell lung cancer were treated in a prospective, randomized trial either with a four-drug combination of cisplatin, doxorubicin, cyclophosphamide, and vindesine (PACE) or with a three-drug combination of cisplatin, cyclopyhosphamide, and vindesine (PCE). None of these patients had received prior chemotherapy, and all had a Karnofsky performance status of at least 60. Of 68 evaluable patients, 21 (31%) had complete or partial remissions. Response rates for PACE and PCE were similar, and there was no difference in response rates for patients with adenocarcinoma or epidermoid cancer. The median duration of remission was 10 months (range, 2-26+); five patients are still in remission (median, 18+ months; range, 17+ to 26+). The median duration of survival for responding patients (complete or partial) was 18 months. Toxic effects, including mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, were manageable in general. The response rates and remission durations for PACE and PCE are similar to those seen with the two-drug combination of cisplatin and vindesine, and toxic effects are similar. Thus, the addition of doxorubicin and/or cyclophosphamide adds no advantage to the use of the cisplatin and vindesine combination alone.

UR - http://www.scopus.com/inward/record.url?scp=0020068092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020068092&partnerID=8YFLogxK

M3 - Article

C2 - 7034932

AN - SCOPUS:0020068092

VL - 66

SP - 247

EP - 251

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -